Skip to main content
. 2021 Nov 15;145(3):184–193. doi: 10.1161/CIRCULATIONAHA.121.057812

Figure 5.

Figure 5.

Responder analysis with proportion of responders at 12, 32, and 52 weeks with empagliflozin versus placebo. CSS indicates Clinical Summary Score; OSS, Overall Summary Score; and TSS, Total Symptom Score.